Anduril raised a $5B Series H led by Thrive and a16z at a $61B valuation, up from $30.5B in June 2025, taking its total funding to $6.82B, and could IPO in 2027
The start-up, which makes A.I.-backed weapons, was valued at $61 billion in the financing round, double what it was a year ago.
Context & Ripple Effects
Anduril’s latest round completes a rapid valuation climb documented across its financing history: from discussions around a $12.5B-plus valuation in 2024, to $14B in its Series F, $30.5B in its 2025 Series G, and now $61B. The March reports had already indicated that Thrive and a16z were pursuing a roughly $4B round at about a $60B valuation.
The company has repeatedly used large private financings rather than moving immediately to public markets. This round increases cumulative funding to $6.82B and gives the company additional private-market backing as it considers a potential 2027 IPO.
First-order effects
- Anduril receives $5B of new capital, materially expanding its financial capacity while its valuation doubles from the June 2025 Series G level.
- Thrive and a16z become the named lead investors in a financing that establishes a new $61B private-market benchmark for Anduril.
Second-order effects
- The round raises the capital and valuation reference point for other defense-technology startups seeking late-stage funding, while increasing pressure on them to show a credible path to similarly scaled operations.
- A larger private capital base may let Anduril defer an IPO decision, shifting more of the near-term value creation and liquidity expectations to its private investors.
Third-order effects
- If successive mega-rounds continue, defense technology could develop a more durable late-stage private-financing market, allowing a small set of companies to fund expansion before accessing public markets.
- Anduril’s prospective 2027 IPO would test whether public investors will support valuations established in private rounds for AI-backed defense businesses; the answer could influence how peers finance themselves.
The trend: Anduril is part of a broader shift in which defense-focused AI companies seek venture-scale private capital and reach public-market scale before going public.